'Hope on horizon' as new drugs tested for Alzheimer's treatment
Some 138 new treatments are being assessed for the treatment and prevention of Alzheimer's.
A third of drugs currently being trialled are "repurposed" medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review.
One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia.
And four late-stage trials are looking at preventing disease.
Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are "only one part of the overall strategy" as they expressed excitement over the variety of new drugs, which are being tested among patients.
The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs.
The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions.
Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: "This year has really given us real cause for optimism."
She said that as well as more drugs coming through the pipeline, the treatment targets are "more diverse" and "looking at all stages of the disease".
She added: "What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating."
"This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab."
Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: "Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia.
"This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments."
James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: "What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal."
On the drugs which are being investigated for the prevention of disease, Prof Rowe said: "One of the most exciting things of this report is the number of large-scale late-stage trials on prevention.
"And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today."
He added: "One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years.
"The ones that are in trial at the moment are really... bringing forward an effective treatment to earlier stage."
For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease.
On the repurposing of current drugs, Dr Mead said that it can usually take ten to 15 years for new drugs to be tested and approved for use.
"Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases," she said.
"A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment."
Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an "important first step" in the battle against the disease.
The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use.
The National Institute for Health and Care Excellence (NICE) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer.
Dr Scales added: "Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease.
"What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and able to deliver for our patients."
She said studies are showing "even more complexities" around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
an hour ago
- Irish Times
Drugs like Ozempic aren't changing negative narratives around diet and weight
Friends keep asking me what I think about Ozempic . I know they're asking because I've written about food history, gender and eating disorders, but until recently I wasn't sure what I thought, wasn't sure that someone who has never had metabolic disease or lived in a body that attracted comment had any business having opinions about the drugs called GLP1 agonists. I support any development that undermines the idea that bodyweight has a moral aspect, or that individuals control the size of their bodies. We are shaped in every way by environment, society and genetics far more than by the small scope of personal choice within those determinants. Health is mostly determined by heredity and wealth. So if the new drugs stop people insisting that self-discipline and self-starvation are the answer to fatness, all to the good. [ Sarah Moss: 'I'm a classic first child. A driven overachiever. Slightly neurotic' Opens in new window ] But I'm not sure they're generally helping us live better lives. I gather GLP1 agonists are good as diabetes medication – not an area in which I am qualified to opine. Their rising use for other purposes seems to be correlated to increasing media excitement about extreme thinness, particularly in women, which is demoralising to those of us who grew up with heroin chic and the worship of emaciation and have lived in the shadow of those ideals ever since. If the drugs are changing narratives about diet and weight, I'm not seeing it. There's no decline in mindless writing about and advertising of 'guilt-free' foods and 'guilty pleasures'. (What you put in your mouth has no bearing on your moral worth. The only sinful foods are those harmfully produced.) READ MORE I understand that these medications work by depriving people of pleasure in eating. I'd argue that pleasure is politically and ideologically important as well as nice, that without pleasure we fall prey to the idea that life is nothing but scarcity and survival, which leads quickly to the idea that life is a competition and weakness is failure, at which point you're well down the road to dark places we don't need to go. Taking expensive drugs to make daily life less fun so you take up less space doesn't sound to me like the kind of choice made by happy people in a functional society, though you could argue that unhappy people in a dysfunctional society – for example, fat people hoping to be paid, promoted and desired as much as their thinner colleagues in Europe today – might perfectly sensibly make such decisions. Getting thin to succeed in a fat-phobic society is still an understandable individual solution to a structural problem. And it seems to me that the big structural problem here is not that people are fat but that we have created and continue to promote a food system that makes most consumers unwell, and are now creating and promoting a regime of medication that, at great financial and personal cost, claims to counteract the effects of that food system. We're all being sold ultra-processed, intensively farmed food that makes us and our planet sick, and then being sold drugs that moderate the effect of that food on individual bodies but compound the harm to the environment. I am certain that the same shareholders profit from the manufacture and sale of the food that causes the problem and the drugs that treat it. Ozempic's popularity is a symptom and driver of social and economic injustice, and I wish we could spend some of its cost on systemic change instead None of which means that I blame any individual for making whatever decisions seem necessary to cope. I only note that the troubles that show up in our bodies rarely began there, and therefore the sustainable solutions won't begin with injections. There are countries that have been able to reduce the proportions of intensively produced and processed foods consumed by their populations, especially by children. There are examples of local, regional and national governments creating and sometimes imposing healthier and more sustainable environments, but it can't happen without at least some popular demand, and the established interests and beneficiaries of harmful systems will never want such change. So what I think about Ozempic is that its popularity is a symptom and driver of social and economic injustice, and I wish we could spend some of its cost on systemic change instead. We could subsidise the production and transport of a lot of fresh local produce and build a lot of playgrounds, sports facilities and bike lanes for what we lose paying pharmaceutical companies to heal us from their absence. And it would be much more fun.
Irish Times
an hour ago
- Irish Times
In Ozempic's home town they fear two things: a new set of tariffs, and a company in Kinsale
It's an overcast morning in the small town of Bagsværd, Denmark , and the streets are empty. The suburb north of Copenhagen looks like any quiet neighbourhood at first glance. It only takes a few minutes to walk the length of the main street, then you start to pass small red brick houses with well-kept gardens. This isn't the type of place where you would expect to find one of Europe's biggest companies. Turn a corner, though, and you suddenly face a long road with row after row of sleek office buildings. In a few short years Novo Nordisk has morphed from a relatively low-profile Danish manufacturer of diabetes medication, into a pharmaceutical giant , on the back of massive demand for its new weight-loss drugs, Ozempic and Wegovy . READ MORE The market value of the company surpassed the size of Denmark's entire economy last year and, for a period, Novo Nordisk was Europe's most valuable company, eclipsing LVMH, the French luxury brand conglomerate that includes Louis Vuitton, Dior and Tiffany. 'I think every second person works there,' says Dorte Soelmark, a woman who runs a bakery nearby Novo Nordisk's headquarters in Bagsværd. The presence of the pharmaceutical giant in the neighbourhood is good for business, but she says there are downsides as well, from traffic bottlenecks to rising house prices. 'You leave at a certain time during the day, the traffic is just horrendous,' Soelmark says. [ Donald Trump says his tariff plan is working - but he now faces a vital call Opens in new window ] Dorte Soelmark, a worker in a bakery near Novo Nordisk's head offices in Bagsværd, Denmark Jesper Chistiansen, who owns a men's clothes shop in a small outlet in the town, says Novo Nordisk's success has been great for Denmark. 'It's very good for the whole country, for the community in Bagsværd,' he says. 'But also it's very expensive to live here.' The company has had a footprint in the Danish town since 1961, when it opened a laboratory. Its presence expanded significantly over the years. New offices for its headquarters were built a decade ago. The company employs 77,000 people, half of whom work in Denmark between Bagsværd and Kalundborg, where it has plans to massively expand a manufacturing plant and other sites. Novo Nordisk's stratospheric rise has been tied to huge demand for its blockbuster weight-loss drugs, Ozempic and Wegovy. The anti-obesity medication inhibits the appetite and is administered by regular injections. Popularised as a way to lose weight by Hollywood celebrities, there had been a global clamour for Ozempic, either prescribed by a doctor or through rapidly expanding black markets selling the jab online. Production has struggled to keep pace, leading to supply shortages. Jesper Chistiansen says Novo Nordisk's success has been great for Denmark Bumper corporate tax receipts from Novo Nordisk have insulated Denmark economically, but also left the public balance sheet exposed to any big downturn in the company's fortunes. The pharma sector – one of Europe's big industrial beasts – is bracing itself for United States president Donald Trump to follow through on threats to levy huge tariffs on its exports to the US. Trump has repeatedly talked about bringing jobs and manufacturing capacity created by US pharma multinationals in Europe back to the US. To do this, the US president has threatened to put tariffs – which are effectively taxes on imports – of up to 200 per cent on pharma products coming across the Atlantic, in an attempt to force companies to make their medicines in the US. The European Union (EU) and the Trump administration have negotiated a deal that would see tariffs on most EU imports capped at 15 per cent , to avoid a trade war. The EU has pressed hard for any future import levies on pharma products to be capped at that blanket 15 per cent rate. However, EU officials remain concerned that regardless of commitments in a preliminary deal, Trump could decide to put sweeping tariffs on pharma anyway down the line. Novo Nordisk is on high alert waiting to see how things play out, like the rest of the industry. Novo Nordisk's stratospheric rise has been tied to huge demand for its blockbuster weight-loss drugs, Ozempic and Wegovy. Photograph: Sergei Gapon/ AFP via Getty Images Separate to the threats coming from Washington, the Danish company is also concerned about what is going on in Kinsale, Co Cork. That's where US pharma giant Eli Lilly has been producing a rival diabetes and weight-loss drug, Mounjaro. The US multinational has made up ground on Novo Nordisk, in the race for the biggest share of the highly profitable anti-obesity market. Research pointing to its drug offering better results, plus successful trials in the development of new medication that can be taken as a daily pill, rather than a weekly injection, has set Eli Lilly up to potentially overtake Novo Nordisk in that race. Fearful of falling behind, Novo Nordisk recently announced a corporate reshuffle. Chief executive Lars Fruergaard Jørgensen, who had been with the company for more than three decades, was out. In a statement announcing the shake-up this May, Novo Nordisk said its sales and profits had almost tripled during Jørgensen's tenure at the top. However, the decision was taken based on 'recent market challenges' and drops in the firm's share price, it said. [ Pharma companies unprepared for production shift amid US tariffs Opens in new window ] In an industry where so much of the focus is on developing new products, the ousting of Jørgensen is a cautionary tale. 'You can be flying one day and the next day you're down on the ground,' says one source in another pharma company. In Belgium, the pharmaceutical industry is managing the fall off of a different type of recent boom in business. The small country was a big producer of Covid-19 vaccines. A Pfizer factory in the north of the country in Puurs, worked full throttle during the height of the pandemic. One of the company's largest plants, it can produce 500 million vaccine doses a year. Covid-19 vaccines accounted for a third of Belgium's pharma exports in 2022, according to a recent industry report. Pharma is one of Belgium's biggest exports, with the US accounting for about a quarter of that trade. Trump's tariff agenda has caused serious uncertainty, says Liesbet Sommen, a centre-right MEP from Belgium. 'One day he says one thing and the next day he says another,' she adds. Huge numbers of people were employed by Belgium's 'pharma valley', so the stakes are high, she says. Several sources in the industry say companies would likely have to suck up the cost of US tariffs, rather than pass part of them on. This is because they are locked into long-term contracts on pricing in the US. Accepting import taxes of 15 per cent would be a hit. About a dozen of the EU's 27 states host sizeable pharma industries. Photograph: Sergei Gapon/ AFP via Getty Images Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations, says part of the problem is the intertwined nature of supply chains. 'There's no product that is made in one country. Sometimes products cross the Atlantic a couple of times before they are finished, so if you had tariffs on one side, and or the other side, you would end up adding cost to that product,' she says. 'There's really a danger of completely destabilising the supply of medicines for patients, wherever that might be in the world,' she says. This is a point the industry has spent a lot of lobbying capital in Washington trying to drive home to the Trump administration. About a dozen of the EU's 27 states host sizeable pharma industries, though few governments are feeling as exposed as Ireland. Pharmaceuticals account for a huge portion of the Republic's large flow of exports to the US. Several US multinationals, Pfizer, Merck Sharp & Dohme (MSD), Eli Lilly, Johnson & Johnson (J&J) and others, have manufacturing plants in Ireland. The sector employs tens of thousands of people and a handful of those companies alone account for a decent chunk of the State's corporate tax take each year. When talking about pharma, Trump repeatedly singles out Ireland as having 'stolen' those jobs and revenues from the US. [ Irish exports climb to €134.4bn as US pharma sales surge Opens in new window ] Documents obtained by The Irish Times show the pharma industry has kept up that lobbying pressure, in both Dublin and Brussels. Photograph: Sergei Gapon/ AFP via Getty Images Taoiseach Micheál Martin has compared notes with several senior pharma executives about the best way to manage Trump's threats. Martin spoke to Pfizer's global chief executive, Albert Bourla, on the phone the day after Trump announced his 'liberation day' tariffs on nearly all global trading partners in early April. The Taoiseach outlined the thinking in the EU, while Bourla 'updated on discussions and contacts with the US administration,' a note of the call said. Separate calls on the same day with Robert Davis, chief executive of MSD, and Joaquin Duato, the chief executive of J&J, covered much the same ground. Tariffs weren't the only thing on the mind of the pharma executives, Davis also mentioned planned reforms of the EU's regulations governing the sector, according to a note taken of the call. The proposed changes would cut back a current eight-year window pharma companies have to exclusively sell new drugs they produce, before cheaper generic competitors enter the market. The idea is to tie more strings to the number of years of market dominance drugmakers enjoy over new medicines, to push companies to roll out medicines in smaller and poorer EU states more quickly. The industry has been furiously lobbying national capitals to kill that element of the proposed overhaul. A parallel lobbying campaign has been waged in Brussels, targeting MEPs in the European Parliament and the European Commission, the EU's executive arm that proposed the reforms. Documents obtained by The Irish Times show the pharma industry has kept up that lobbying pressure, in Dublin and Brussels. The risk posed by Trump's potential tariffs has strengthened the industry's hand when arguing that now is not the time for such changes. Employees are seen through windows as they work at the Novo Nordisk headquarters in Denmark. Photograph: Sergei Gapon/ AFP via Getty Images In a letter on March 7th to a senior adviser of EU industry commissioner Stéphane Séjourné, Pfizer said there was an 'urgent need' for Europe to do more to be economically competitive, due to 'recent geopolitical developments'. The commission's plan to cut back firms' regulatory protection over new medicines was 'not the right approach,' Michaela Hagenhofer, head of J&J's Irish operation, told Minister for Enterprise Peter Burke . The February 25th letter asked Ireland to join the Coalition of 'pro-innovation' countries opposing the changes at EU-level. Samantha Humphreys, MSD's Irish director, urged the Government to maintain the 'status quo', in a February 11th letter. The correspondence was released to The Irish Times following Freedom of Information Act requests. Further internal records reveal the Department of Health wanted Ireland to stick to its 'more balanced' view that some changes were needed, according to a March 18th briefing paper. [ Looming 'patent cliff' facing Big Pharma adds to sector's woes Opens in new window ] In the end the Taoiseach came down on the side of industry in the debate. Ireland switched positions and joined the camp of countries opposed to diluting the 'protection' firms had over new drugs they developed. National capitals settled on keeping the eight-year window untouched, in an EU vote earlier this year. A pared back version of the new regulations are likely to be signed off in the coming months, in what will be a significant win for the pharma sector. Many of the industry's top executives have probably spent recent months wishing they could command the same level of influence over policy in the White House, given the fight over tariffs that is likely still to come.
Irish Independent
3 hours ago
- Irish Independent
Wicklow adventurer to take on 750km cycling challenge for charity
Nigel Jenkinson of Redcross got back into cycling in 2022 after training with a friend for a Quest event, which consisted of a mixture of running, cycling and kayaking. He then decided to partake in the Ring of Clare 2022 160km cycle challenge. Now he has set himself a new challenge, involving a 750km cycle across France. 'A few years ago I got back on my bike and set myself a challenge of cycling 160km event. I applied to take part in the Ring of Clare and was hooked, I decided to raise money for a local charity and I called into Wicklow Cancer Support and raised over €2,000 for them. 'Now this September, I'm trading my comfy couch for a bike seat and embarking on a six-day cycling odyssey from Paris to Nice, because why not go big or go home,' said Nigel. The charity ride starts on September 6, and Nigel is under no illusions over just how challenging the venture will prove, from both a mental and physical perspective. 'I'll be tackling everything from the charming streets of Montargis to the legendary climbs of Mount Ventoux. It's a journey that promises to test my legs, my resolve, and my ability to pronounce French town names correctly. 'But this isn't just about proving I can survive on energy gels and questionable French pastries. I'm pedalling for a purpose: raising funds for the Alzheimer's Society of Ireland. This cause is close to my heart, as my family, like many others, has been touched by the challenges of Alzheimer's.' In Ireland, approximately 64,000 people are currently living with dementia. This number is projected to more than double by 2045, reaching an estimated 150,131, due to the increasing and aging population. Nigel has established an idonate page to help raise funds for the Alzheimer's Society of Ireland and will be covering all the costs associated with the trip from his own pocket. He added: 'I'm covering all my own costs, so every euro you donate goes straight to supporting vital services and research for those affected by dementia in Ireland. With 11,000 new cases diagnosed each year, and numbers expected to rise, your support is more important than ever.' Nigel will be sharing regular updates on his training progress, and once he sets off on his journey, he will also provide daily updates from the event itself.
